| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.50.3.669 |
| P698 | PubMed publication ID | 9521254 |
| P50 | author | Martin R. Farlow | Q67212573 |
| P2093 | author name string | Poirier J | |
| Davignon J | |||
| Lahiri DK | |||
| Hui SL | |||
| Schneider L | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 669-677 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. | |
| P478 | volume | 50 |
| Q28085213 | APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective |
| Q37044205 | APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease |
| Q21090806 | Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use |
| Q34111025 | Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression |
| Q34192420 | Alzheimer's disease: current and future therapeutic perspectives |
| Q34431008 | Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. |
| Q57782073 | Antihypertensive drugs and incidence of dementia: the Rotterdam Study |
| Q43990900 | ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model |
| Q30341746 | ApoE-dependent plasticity in Alzheimer's disease. |
| Q37821616 | Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. |
| Q34145767 | Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues |
| Q37846932 | Apolipoprotein E in Alzheimer's disease and other neurological disorders |
| Q97570193 | Apolipoprotein E ε-4 as a genetic determinant of Alzheimer's disease heterogeneity |
| Q34808510 | Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction |
| Q33599089 | Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease |
| Q37073034 | Arabidopsis thaliana extracts optimized for polyphenols production as potential therapeutics for the APOE-modulated neuroinflammation characteristic of Alzheimer's disease in vitro |
| Q50800255 | BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. |
| Q34459045 | Candidate gene case-control association studies: advantages and potential pitfalls |
| Q32058561 | Cholinesterase inhibitors for Alzheimer's disease. |
| Q36475090 | Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story |
| Q38397411 | Cognitive predictors of donepezil therapy response in Alzheimer disease |
| Q35066849 | Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. |
| Q34110671 | Current and future clinical trials for Alzheimer's disease: evolving ethical concerns |
| Q45004319 | Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers |
| Q46439014 | Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease? |
| Q33791482 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease |
| Q51847733 | Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. |
| Q46778332 | Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease |
| Q37369200 | Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group |
| Q43648552 | Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease |
| Q44094534 | Evidence for parent of origin effect in late-onset Alzheimer disease |
| Q35076662 | Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. |
| Q31754077 | Galantamine: a review of its use in Alzheimer's disease |
| Q52170510 | Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats. |
| Q34134818 | Genetic susceptibility factors for Alzheimer's disease. |
| Q37462565 | Genetics in clinical trials |
| Q38088754 | Genomics and proteomics are changing discovery, development and clinical use of dementia drugs. |
| Q62395629 | Hippocampal structure and the action of cholinomimetic drugs |
| Q44303602 | Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study |
| Q57995824 | Human Apolipoprotein E concentration in response to diseases and therapeutic treatments |
| Q34783722 | Immunotherapy for Alzheimer's disease |
| Q40081341 | Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. |
| Q48509968 | Investigating gender differences in outcome following severe traumatic brain injury in a predominantly Asian population. |
| Q90390163 | M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera |
| Q57445890 | Making drug discovery a SN(i)P |
| Q42644052 | Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients |
| Q90114589 | Mitochondria Targeted Therapeutics for Alzheimer's Disease: The Good. The Bad. The Potential |
| Q44251907 | Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. |
| Q58610758 | Molecular differences in Alzheimer's disease between male and female patients determined by integrative network analysis |
| Q34976296 | Neuroplasticity in Alzheimer's disease |
| Q35814369 | Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q37967607 | Pharmacogenomics in neurology: current state and future steps |
| Q34134861 | Pharmacogenomics of psychiatric disorders |
| Q33688768 | Recent developments in the drug treatment of Alzheimer's disease |
| Q38495339 | Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. |
| Q91706991 | Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks |
| Q60637417 | Sex differences in Alzheimer disease — the gateway to precision medicine |
| Q40479885 | Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. |
| Q35207554 | The application of functional genomics to Alzheimer's disease |
| Q44872673 | The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. |
| Q33624389 | The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging |
| Q42560979 | The perils of Alzheimer's drug development |
| Q33858831 | The potential applications of Apolipoprotein E in personalized medicine |
| Q34204390 | The status of ongoing trials for mild cognitive impairment |
| Q35236387 | Therapeutic approaches to age-associated neurocognitive disorders |
| Q39380813 | Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions |
| Q34115616 | Why should primary care physicians know about the genetics of dementia? |
| Q52532967 | [Treatment of Alzheimer' disease: critical evaluation of the use of anticholinesterase] |
Search more.